Prospects and limitations of T cell receptor gene therapy

Current Gene Therapy

Volumn 11, Issue 4, 2011, Pages 276-287

  Jorritsma, Annelies ^a   Schotte, Remko ^a   Coccoris, Miriam ^b   de Witte, Moniek A ^c   Schumacher, Ton N M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Adoptive therapy; Gene therapy; Major histocompatibility complex (MHC); T cell receptor (TCR); T lymphocytes

Indexed keywords

ANTIBODY; CARBONATE DEHYDRATASE; CARCINOEMBRYONIC ANTIGEN; CYCLIN D1; DIFFERENTIATION ANTIGEN; EPITOPE; EPSTEIN BARR VIRUS ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INFLUENZA A NUCLEOPROTEIN; INTERLEUKIN 2; LENTIVIRUS VECTOR; MINOR HISTOCOMPATIBILITY ANTIGEN; NEO ANTIGEN; PROTEIN MDM2; PROTEIN P53; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; TUMOR SPECIFIC TRANSPLANTATION ANTIGEN; UNCLASSIFIED DRUG; VIRUS VACCINE; WT1 PROTEIN;

ACTIVE IMMUNIZATION; ADOPTIVE TRANSFER; ALLOGENEIC RESTRICTION; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CANCER CONTROL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL THERAPY; COLORECTAL CANCER; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS ASSOCIATED B CELL LYMPHOMA; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENE THERAPY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INFLUENZA VIRUS A; LENTIVIRINAE; LEUKEMIA; LEUKEMIA CELL; LIVER METASTASIS; LUNG METASTASIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MALIGNANT TRANSFORMATION; MELANOCYTE; MELANOMA; META ANALYSIS (TOPIC); NONHUMAN; ONCOGENE; PANCREAS ISLET BETA CELL; PASSIVE IMMUNIZATION; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL (TOPIC); PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA; PROTEIN EXPRESSION; RETROVIRUS; REVIEW; SIGNAL TRANSDUCTION; SUICIDE GENE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE RECEPTOR ALPHA GENE; T LYMPHOCYTE RECEPTOR BETA GENE; T LYMPHOCYTE RECEPTOR GENE; T LYMPHOCYTE RECEPTOR GENE THERAPY INDUCED GRAFT VERSUS HOST DISEASE; TARGET CELL; TRANSGENIC MOUSE; TRANSPOSON; TRANSPOSON MEDIATED GENE DELIVERY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; WART VIRUS; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

ADOPTIVE TRANSFER; ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RETROVIRIDAE; T-LYMPHOCYTES;

EID: 79960008541     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652311796150390     Document Type: Review

References (112)

1. van Heijst JW, Gerlach C, Swart E, et al. Recruitment of antigenspecific CD8+ T cells in response to infection is markedly efficient. Science 2009; 325: 1265-1269.
2. De Visser KE, Schumacher TN, Kruisbeek AM. CD8+ T cell tolerance and cancer immunotherapy. J Immunother 2003; 26: 1-11.
3. Dupage M, Cheung AF, Mazumdar C, et al. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 2011; 19: 72-85.
4. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005; 437: 141-146.
5. Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis- restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci U S A 2003; 100: 2742-2747.
6. Dazzi F, Goldman JM. Adoptive immunotherapy following allogeneic bone marrow transplantation. Annu Rev Med 1998; 49: 329-340.
7. Gottschalk S, Heslop HE, Rooney CM. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma 2005; 46: 1-10.
8. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-854.
9. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346-2357.
10. Besser MJ, Shapira-Frommer R, Treves AJ, et al. Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients. Clin Cancer Res 2010.
11. Calogero A, Hospers GA, Kruse KM, et al. Retargeting of a T cell line by anti MAGE-3/HLA-A2 alpha beta TCR gene transfer. Anticancer Res 2000; 20: 1793-1869.
12. Clay TM, Custer MC, Sachs J, et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 1999; 163: 507-513.
13. Cooper LJ, Kalos M, Lewinsohn DA, Riddell SR, Greenberg PD. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol 2000; 74: 8207-8212.
14. Fujio K, Misaki Y, Setoguchi K, et al. Functional reconstitution of class II MHC-restricted T cell immunity mediated by retroviral transfer of the alpha beta TCR complex. J Immunol 2000; 165: 528-532.
15. Heemskerk MH, Hoogeboom M, Hagedoorn R, et al. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med 2004; 199: 885-894.
16. Orentas RJ, Roskopf SJ, Nolan GP, Nishimura MI. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virusencoded peptide. Clin Immunol 2001; 98: 220-228.
17. Labrecque N, Whitfield LS, Obst R, et al. How much TCR does a T cell need? Immunity 2001; 15: 71-82.
18. Kessels HW, Wolkers MC, van den Boom MD, van der Valk MA, Schumacher TN. Immunotherapy through TCR gene transfer. Nat Immunol 2001; 2: 957-961.
19. Heslop HE, Rooney CM. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev 1997; 157: 217-222.
20. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virusspecific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9-13.
21. Kurts C, Miller JF, Subramaniam RM, Carbone FR, Heath WR. Major histocompatibility complex class I-restricted crosspresentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med 1998; 188: 409-414.
22. de Witte MA, Coccoris M, Wolkers MC, et al. Targeting selfantigens through allogeneic TCR gene transfer. Blood 2006; 108: 870-877.
23. de Witte MA, Jorritsma A, Kaiser A, et al. Requirements for effective antitumor responses of TCR transduced T cells. J Immunol 2008; 181: 5128-5136.
24. de Witte MA, Bendle GM, van den Boom MD, et al. TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J Immunol 2008; 181: 2563-2571.
25. Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001; 194: 823-832.
26. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 2001; 7: 1118-1122.
27. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002; 3: 611-618.
28. Bendle GM, Linnemann C, Hooijkaas AI, et al. Lethal graftversus- host disease in mouse models of T cell receptor gene therapy. Nat Med 2010; 16: 565-570, 1p.
29. Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol 2002; 2: 512-519.
30. van Loenen MM, de Boer R, Amir AL, et al. Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc Natl Acad Sci U S A 2010; 107: 10972-10977.
31. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129.
32. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114: 535-546.
33. Parkhurst MR, Yang JC, Langan RC, et al. T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. Mol Ther 2010.
34. Kawakami Y, Rosenberg SA. T-cell recognition of self peptides as tumor rejection antigens. Immunol Res 1996; 15: 179-190.
35. Morgan RA, Dudley ME, Yu YY, et al. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 2003; 171: 3287-3295.
36. Schaft N, Willemsen RA, de Vries J, et al. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J Immunol 2003; 170: 2186-2194.
37. Roszkowski JJ, Lyons GE, Kast WM, et al. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviralmediated transfer of a single T-cell receptor. Cancer Res 2005; 65: 1570-1576.
38. Hughes MS, Yu YY, Dudley ME, et al. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther 2005; 16: 457-472.
39. Zhao Y, Zheng Z, Robbins PF, et al. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol 2005; 174: 4415-4423.
40. Johnson LA, Heemskerk B, Powell DJ, Jr., et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumorinfiltrating lymphocytes. J Immunol 2006; 177: 6548-6559.
41. Jorritsma A, Gomez-Eerland R, Dokter M, et al. Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood 2007; 110: 3564-3572.
42. Chhabra A, Yang L, Wang P, et al. CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model. J Immunol 2008; 181: 1063-1070.
43. Frankel TL, Burns WR, Peng PD, et al. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. J Immunol 2010; 184: 5988-5998.
44. Zippelius A, Pittet MJ, Batard P, et al. Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med 2002; 195: 485-494.
45. Sadovnikova E, Jopling LA, Soo KS, Stauss HJ. Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur J Immunol 1998; 28: 193-200.
46. Savage P, Gao L, Vento K, et al. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood 2004; 103: 4613-4615.
47. de Witte M, Schumacher T. Generating CTL by HLA transplant. Blood 2004; 103: 4381-4382.
48. Holler PD, Holman PO, Shusta EV, et al. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc Natl Acad Sci U S A 2000; 97: 5387-5392.
49. Kessels HW, van den Boom MD, Spits H, Hooijberg E, Schumacher TN. Changing T cell specificity by retroviral T cell receptor display. Proc Natl Acad Sci U S A 2000; 97: 14578-14583.
50. Shusta EV, Holler PD, Kieke MC, Kranz DM, Wittrup KD. Directed evolution of a stable scaffold for T-cell receptor engineering. Nat Biotechnol 2000; 18: 754-759.
51. Li Y, Moysey R, Molloy PE, et al. Directed evolution of human Tcell receptors with picomolar affinities by phage display. Nat Biotechnol 2005; 23: 349-354.
52. Varela-Rohena A, Molloy PE, Dunn SM, et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med 2008; 14: 1390-1395.
53. Robbins PF, Li YF, El Gamil M, et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol 2008; 180: 6116-6131.
54. Zhao Y, Bennett AD, Zheng Z, et al. High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J Immunol 2007; 179: 5845-5854.
55. Stanislawski T, Voss RH, Lotz C, et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2001; 2: 962-970.
56. Kuball J, Schmitz FW, Voss RH, et al. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 2005; 22: 117-129.
57. Davis JL, Theoret MR, Zheng Z, et al. Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clin Cancer Res 2010; 16: 5852-5861.
58. Bruggemann M, Winter G, Waldmann H, Neuberger MS. The immunogenicity of chimeric antibodies. J Exp Med 1989; 170: 2153-2157.
59. Li LP, Lampert JC, Chen X, et al. Transgenic mice with a diverse human T cell antigen receptor repertoire. Nat Med 2010; 16: 1029-1034.
60. Bruggemann M, Neuberger MS. Strategies for expressing human antibody repertoires in transgenic mice. Immunol Today 1996; 17: 391-397.
61. Overwijk WW, Lee DS, Surman DR, et al. Vaccination with a recombinant vaccinia virus encoding a self antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A 1999; 96: 2982-2987.
62. Palmer DC, Chan CC, Gattinoni L, et al. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A 2008; 105: 8061-8066.
63. Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18: 843-851.
64. Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006; 24: e20-e22.
65. Mitchell R, Beitzel B, Schroder A, et al. Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences. PLoS Biology 2004; 2: e234.
66. Schambach A, Baum C. Clinical application of lentiviral vectors - concepts and practice. Curr Gene Ther 2008; 8: 474-482.
67. Cavazzana-Calvo M, Hacein-Bey S, Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-672.
68. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-41
69. Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010; 363: 355-364.
70. Newrzela S, Cornils K, Li Z, et al. Resistance of mature T cells to oncogene transformation. Blood 2008; 112: 2278-2286.
71. Bonini C, Grez M, Traversari C, et al. Safety of retroviral gene marking with a truncated NGF receptor. Nat Med 2003; 9: 367-369.
72. Recchia A, Bonini C, Magnani Z, et al. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc Natl Acad Sci U S A 2006; 103: 1457-1462.
73. Huang X, Wilber AC, Bao L, et al. Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. Blood 2006; 107: 483-491.
74. Peng PD, Cohen CJ, Yang S, et al. Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Ther 2009; 16: 1042-1049.
75. Hackett PB, Largaespada DA, Cooper LJ. A transposon and transposase system for human application. Mol Ther 2010; 18: 674-683.
76. Haas J, Park EC, Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol 1996; 6: 315-324.
77. Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res 2006; 66: 8878-8886.
78. Bialer G, Horovitz-Fried M, Ya'acobi S, Morgan RA, Cohen CJ. Selected murine residues endow human TCR with enhanced tumor recognition. J Immunol 2010; 184: 6232-6241.
79. Sommermeyer D, Uckert W. Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells. J Immunol 2010; 184: 6223-6231.
80. Cohen CJ, Li YF, El Gamil M, et al. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res 2007; 67: 3898-3903.
81. Kuball J, Dossett ML, Wolfl M, et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 2007; 109: 2331-2338.
82. de Felipe P, Martin V, Cortes ML, Ryan M, Izquierdo M. Use of the 2A sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy. Gene Ther 1999; 6: 198-208.
83. Klump H, Schiedlmeier B, Vogt B, et al. Retroviral vectormediated expression of HoxB4 in hematopoietic cells using a novel coexpression strategy. Gene Ther 2001; 8: 811-817.
84. Bevan MJ. Helping the CD8(+) T-cell response. Nat Rev Immunol 2004; 4: 595-602.
85. Morris EC, Tsallios A, Bendle GM, Xue SA, Stauss HJ. A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc Natl Acad Sci U S A 2005; 102: 7934-7939.
86. Wright GP, Notley CA, Xue SA, et al. Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc Natl Acad Sci U S A 2009; 106: 19078-19083.
87. Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005; 115: 1616-1626.
88. Klebanoff CA, Gattinoni L, Torabi-Parizi P, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A 2005; 102: 9571-9576.
89. Gattinoni L, Zhong XS, Palmer DC, et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med 2009; 15: 808-813.
90. Kaneko S, Mastaglio S, Bondanza A, et al. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood 2008.
91. Berger C, Jensen MC, Lansdorp PM, et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008; 118: 294-305.
92. Yang L, Baltimore D. Long-term in vivo provision of antigenspecific T cell immunity by programming hematopoietic stem cells. Proc Natl Acad Sci U S A 2005; 102: 4518-4523.
93. Dontje W, Schotte R, Cupedo T, et al. Delta-like1-induced Notch1 signaling regulates the human plasmacytoid dendritic cell versus Tcell lineage decision through control of GATA-3 and Spi-B. Blood 2006; 107: 2446-2452.
94. Motte-Mohs RN, Herer E, Zuniga-Pflucker JC. Induction of T-cell development from human cord blood hematopoietic stem cells by Delta-like 1 in vitro. Blood 2005; 105: 1431-1439.
95. van Lent AU, Nagasawa M, van Loenen MM, et al. Functional human antigen-specific T cells produced in vitro using retroviral T cell receptor transfer into hematopoietic progenitors. J Immunol 2007; 179: 4959-4968.
96. Zhao Y, Parkhurst MR, Zheng Z, et al. Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. Cancer Res 2007; 67: 2425-2429.
97. Dudley ME, Wunderlich JR, Yang JC, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 2002; 25: 243-251.
98. Goldrath AW, Bogatzki LY, Bevan MJ. Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp Med 2000; 192: 557-564.
99. Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol 2005; 26: 111-117.
100. Paulos CM, Wrzesinski C, Kaiser A, et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest 2007; 117: 2197-2204.
101. Sportes C, Hakim FT, Memon SA, et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008; 205: 1701-1714.
102. Klebanoff CA, Finkelstein SE, Surman DR, et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A 2004; 101: 1969-1974.
103. Alpdogan O, Eng JM, Muriglan SJ, et al. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood 2005; 105: 865-8673.
104. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
105. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003; 100: 8372-8377.
106. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005; 23: 741-750.
107. Vera JF, Brenner MK, Dotti G. Immunotherapy of human cancers using gene modified T lymphocytes. Curr Gene Ther 2009; 9: 396-408.
108. Wang Q, Chaerkady R, Wu J, et al. Mutant proteins as cancerspecific biomarkers. Proc Natl Acad Sci U S A 2011.
109. Gotter J, Brors B, Hergenhahn M, Kyewski B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med 2004; 199: 155-156.
110. Toebes M, Coccoris M, Bins A, et al. Design and use of conditional MHC class I ligands. Nat Med 2006; 12: 246-251.
111. Hadrup SR, Bakker AH, Shu CJ, et al. Parallel detection of antigen- specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods 2009; 6: 520-52
112. Newell EW, Klein LO, Yu W, Davis MM. Simultaneous detection of many T-cell specificities using combinatorial tetramer staining. Nat Methods 2009; 6: 497-549